Core Insights - Halozyme Therapeutics, Inc. will present at the 8th Annual Evercore Healthcare Conference on December 2, 2025, at 10:20 am PT / 1:20 pm ET, hosted by Dr. Helen Torley, the president and CEO [1] Company Overview - Halozyme is a biopharmaceutical company focused on innovative solutions to enhance patient experiences and outcomes for both emerging and established therapies [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of injected drugs, improving convenience and reducing treatment burden [4] - ENHANZE® has impacted over one million patients through ten commercialized products across more than 100 global markets, with partnerships involving major pharmaceutical companies such as Roche, Takeda, and Pfizer [4] Technology Development - Halozyme is developing Hypercon™, a microparticle technology aimed at hyper-concentration of drugs and biologics, which is expected to reduce injection volume while expanding at-home and healthcare provider administration opportunities [5] - The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson & Johnson and Eli Lilly, enhancing the company's drug delivery capabilities [5] Product Portfolio - The company also develops drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence, with proprietary products like Hylenex® and XYOSTED® [6] - Halozyme has ongoing development programs in collaboration with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. [6] Corporate Information - Halozyme is headquartered in San Diego, California, with additional offices in Ewing, New Jersey; Minnetonka, Minnesota; and Boston, Massachusetts [7]

Core Points - Genmab A/S announced the pricing of $1.5 billion of 6.250% senior secured notes due 2032 and $1.0 billion of 7.250% senior unsecured notes due 2033, with an issue price of 100.000% [1] - The company has completed the syndication of a new $2.0 billion senior secured term loan "B" facility, in addition to existing credit facilities [2] - The net proceeds from the notes offering will be used to fund the acquisition of Merus N.V. and related expenses [3] Financing Details - The total financing includes $1.5 billion in secured notes and $1.0 billion in unsecured notes, alongside a $2.0 billion senior secured term loan "B" facility [1][2] - The secured notes will be backed by segregated accounts prior to the acquisition closing, and will later be secured by a first priority interest in certain assets of Genmab and its subsidiaries [4] - The indentures governing the notes will include covenants that restrict Genmab and its subsidiaries from incurring additional debt and other financial activities [5] Regulatory Information - The notes have not been registered under the Securities Act and are available only to qualified institutional buyers or non-U.S. persons [6] - The offering does not constitute an offer to sell or a solicitation of an offer to purchase any securities [7]

Core Insights - Merus N.V. and Halozyme Therapeutics, Inc. have entered into a global non-exclusive collaboration and license agreement to develop and potentially commercialize the subcutaneous administration of petosemtamab, an EGFR x LGR5 bispecific antibody [1][2][3] Company Overview - Halozyme is a biopharmaceutical company known for its ENHANZE drug delivery technology, which facilitates subcutaneous delivery of injected drugs, aiming to improve patient experience and treatment efficiency [4][5] - Merus specializes in developing innovative full-length multispecific antibodies and antibody drug conjugates, referred to as Multiclonics, which have shown promising results in clinical studies [7][8] Collaboration Details - Under the agreement, Merus will make an upfront payment to Halozyme, along with potential future milestone payments based on commercial and sales achievements, if approved [3] - Halozyme is entitled to receive low to mid-single digit royalties on net sales of petosemtamab formulated with the ENHANZE technology during the royalty term [3] Clinical Potential - Petosemtamab has shown encouraging results in clinical studies across various solid tumor cancers and is positioned to potentially become a first and best-in-class treatment for head and neck cancer and other indications [2][3]

Core Points - Genmab A/S announced plans to offer $1.5 billion of senior secured notes due 2032 and $1.0 billion of senior unsecured notes due 2033, alongside a new $2.0 billion senior secured term loan "B" facility [1] - The financing is part of the acquisition of Merus N.V., which includes previously syndicated credit facilities totaling $1.5 billion [1] - A preliminary offering memorandum has been provided to potential investors, containing undisclosed information and pro forma financial data related to the acquisition [2] Financial Information - The preliminary offering memorandum includes unaudited pro forma condensed combined financial information for the nine months ended September 30, 2025, and for the year ended December 31, 2024 [2] - Audited consolidated financial statements for the years ended December 31, 2024, 2023, and 2022 are also included, originally prepared in Danish Kroner and retranslated into US Dollars [2]

Core Viewpoint - Genmab A/S announced plans to offer $1.5 billion of senior secured notes due 2032 and $1.0 billion of senior unsecured notes due 2033 to finance the acquisition of Merus N.V. [1][2][3] Financing Details - The company is launching a new $2.0 billion senior secured term loan "B" facility, in addition to a previously syndicated $1.0 billion senior secured term loan "A" facility and a $500 million senior secured revolving credit facility [2] - The net proceeds from the offering of the Notes, along with borrowings under the New Credit Facilities and cash on hand, will be used to fund the acquisition of Merus and related expenses [3] Security and Guarantees - Prior to the acquisition closing, the Notes will be secured by segregated securities accounts of Genmab, with the gross proceeds held therein [4] - After the acquisition, the Secured Notes will be secured by a first priority security interest in certain assets of Genmab and its subsidiaries [4] Indenture Covenants - The indentures governing the Notes are expected to include customary covenants that restrict Genmab and its subsidiaries from incurring additional debt, paying dividends, and engaging in certain transactions without exceptions [5] Regulatory Information - The Notes will not be registered under the Securities Act of 1933 and will only be available to qualified institutional buyers or non-U.S. persons outside the United States [6]

Financial Performance - Total revenue grew by 21% to USD 2,662 million for the first nine months of 2025 [43] - Operating profit increased by 52% to USD 1,007 million for the first nine months of 2025 [12, 43] - Recurring revenue grew by 26% for the first nine months of 2025 [43] - Combined commercialized medicines sales increased by 54% to USD 453 million for the first nine months of 2025 [28] Product Performance - EPKINLY net sales reached USD 333 million, a 64% increase year-over-year for the first nine months of 2025 [31] - TIVDAK net sales reached USD 120 million, a 30% increase year-over-year for the first nine months of 2025 [36] Strategic Initiatives - The company is planning to acquire Merus to deliver the next decade of sustainable growth [12, 14] - The company anticipates a first launch for petosemtamab in 2027 [17] Rina-S® Data - Rina-S® 100mg/m2 led to a confirmed ORR of 50% and a DCR of 100% in patients with advanced or recurrent endometrial cancer [26]

Core Insights - Genmab has made significant advancements in its late-stage portfolio, with Epcoritamab nearing availability for earlier treatment lines in follicular lymphoma and Rina-S receiving Breakthrough Therapy Designation for advanced endometrial cancer [2][6] - The proposed acquisition of Merus is expected to enhance Genmab's late-stage pipeline by adding petosemtamab, which has two Breakthrough Therapy Designations, and is anticipated to drive sustained growth into the next decade [2][8] Financial Performance - Genmab's revenue for the first nine months of 2025 reached $2,662 million, a 21% increase from $2,198 million in the same period of 2024, primarily driven by higher royalties from DARZALEX and Kesimpta, as well as increased net product sales of EPKINLY [6][7] - Royalty revenue increased to $2,219 million in the first nine months of 2025, up from $1,802 million in the same period of 2024, marking a 23% rise [7] - Operating profit for the first nine months of 2025 was $1,007 million, compared to $662 million in the same period of 2024 [7] Strategic Outlook - Genmab is maintaining its financial guidance for 2025 as published on August 7, 2025 [4] - The company has transitioned its functional and presentation currency from DKK to USD effective January 1, 2025, with retrospective adjustments made to prior periods [5] Acquisition Details - Genmab intends to acquire Merus for $97.00 per share in an all-cash transaction valued at approximately $8.0 billion, funded through cash on hand and $5.5 billion of non-convertible debt financing [8] - The acquisition is expected to close by early Q1 2026, subject to customary closing conditions [8]

Group 1 - The markets are experiencing upward movement despite ongoing concerns, including a government shutdown that is approaching its fifth week without resolution [1] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions on trade ideas and weekly research updates [1] Group 2 - The article does not provide specific financial data or performance metrics related to the companies mentioned [2][3]

Core Points - Genmab A/S is initiating a cash tender offer to acquire all outstanding common shares of Merus N.V. for $97.00 per share [1] - The offer is part of a transaction agreement dated September 29, 2025, between Genmab, its subsidiary, and Merus [1] - Merus's Board of Directors has recommended that shareholders accept the offer [2] Offer Details - The tender offer will expire at 5:00 p.m. New York City time on December 11, 2025, unless extended [3] - If conditions are met, a subsequent offering period will commence on the first business day following the expiration [3] - The offer is not subject to a financing condition but is subject to other conditions, including a minimum tender condition [4] Shareholder Information - Merus shareholders are advised to review the tender offer documents filed with the SEC before deciding to tender their shares [5] - These documents can be accessed for free on the SEC's website or through the information agent for the tender offer [5] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics [6] - The company has a vision to transform the lives of patients with cancer and serious diseases through advanced antibody medicines by 2030 [6] - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with a global presence [7]

Core Insights - The article highlights stocks reaching new 52-week highs, indicating market recognition of strong fundamentals and potential catalysts for growth [1][2]. Company Summaries Cogent Biosciences Inc. (COGT) - Cogent Biosciences plans to file its first New Drug Application for Bezuclastinib by the end of 2025, targeting non-advanced systemic mastocytosis [3]. - A phase III trial comparing Bezuclastinib with Sutent is ongoing, with results expected in the second half of 2025 [4]. - The stock reached a 52-week high of $16.99, up from $7.25 when last featured [5]. Assembly Biosciences Inc. (ASMB) - Assembly Biosciences is advancing four key development programs, with ABI-5366 expected to enter phase 2 studies in mid-2026 [6]. - Interim data for ABI-1179 is anticipated this fall, while ABI-6250 is in a phase 1a trial [7]. - The stock hit a 52-week high of $28, up from $14.53 when last featured [8]. Compass Therapeutics Inc. (CMPX) - Compass Therapeutics is conducting a phase 2/3 study of Tovecimig for advanced biliary tract cancer, with analyses of secondary endpoints expected in Q1 2026 [9][10]. - The stock reached a 52-week high of $4.39, up from $2.91 when last featured [11]. NewAmsterdam Pharma Company N.V. (NAMS) - NewAmsterdam Pharma is developing Obicetrapib as a cholesterol-lowering therapy, with positive data from the BROADWAY trial [12][13]. - The company has completed two additional phase III trials and submitted marketing applications to the EMA [16]. - The stock reached a 52-week high of $39.76, up from $21.56 when last featured [17]. Mineralys Therapeutics Inc. (MLYS) - Mineralys is developing Lorundrostat for uncontrolled hypertension, with a pivotal phase III trial achieving its primary endpoint [19]. - A phase II trial for overweight participants with OSA is ongoing, with topline results expected in 1H 2026 [20]. - The stock hit a 52-week high of $43.88, up from $10.34 when last featured [20]. Kymera Therapeutics Inc. (KYMR) - Kymera is set to report data from its phase I trial of KT-621 this quarter, with phase 2b studies planned for late 2025 and early 2026 [21][22]. - The stock reached a 52-week high of $60, up from $40 when last featured [22]. Insmed Inc. (INSM) - Insmed has two approved drugs and is conducting a phase 3 trial of Arikayce, with topline results expected in 1H 2026 [24][25]. - The stock hit a high of $166.54, up from $76.54 when last featured [26]. Adaptive Biotechnologies Corp. (ADPT) - Adaptive Biotechnologies expects MRD revenue between $190 million and $200 million for 2025, up from $145.5 million in 2024 [28][29]. - The stock reached a 52-week high of $15.94, up from $9.80 when last featured [29]. BridgeBio Pharma Inc. (BBIO) - BridgeBio has upcoming topline results from the FORTIFY and CALIBRATE studies expected in Fall 2025 [30]. - The stock reached a 3-year high of $56.24, up from $25.10 when last featured [31]. Tarsus Pharmaceuticals Inc. (TARS) - Tarsus reported strong sales for Xdemvy, with Q2 2025 sales of $102.7 million, compared to $40.8 million in Q2 2024 [32]. - The stock hit an all-time high of $70.15, up from $25.01 when last featured [34]. Palvella Therapeutics Inc. (PVLA) - Palvella's QTORIN is under development for various skin diseases, with a phase 2 trial expected to report data in mid-December 2025 [35][36]. - The stock reached a 52-week high of $76.76, up from $25 when last featured [36]. Merus N.V. (MRUS) - Merus agreed to be acquired by Genmab for $97 per share, with the deal expected to close in early Q1 2026 [37]. - The stock was at $39.71 when last featured [39]. Nephros Inc. (NEPH) - Nephros reported net revenue of $4.4 million for Q2 2025, marking its third consecutive quarter of profitability [40][41]. - The stock hit a 52-week high of $5.98, up from $2.93 when last featured [42].